Skandinaviska Enskilda Banken AB publ Decreases Position in Moderna, Inc. (NASDAQ:MRNA)

Skandinaviska Enskilda Banken AB publ reduced its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 16.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,455 shares of the company's stock after selling 13,348 shares during the period. Skandinaviska Enskilda Banken AB publ's holdings in Moderna were worth $2,616,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc purchased a new stake in Moderna during the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC raised its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after purchasing an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after purchasing an additional 389 shares during the period. Finally, Blue Trust Inc. raised its position in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after purchasing an additional 388 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Moderna Trading Down 2.6 %

Shares of MRNA traded down $0.87 during midday trading on Thursday, hitting $32.45. 5,608,807 shares of the company's stock traded hands, compared to its average volume of 6,572,052. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The firm's fifty day moving average is $35.31 and its 200-day moving average is $46.45. The stock has a market capitalization of $12.52 billion, a price-to-earnings ratio of -3.50 and a beta of 1.86.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MRNA. Royal Bank of Canada restated a "sector perform" rating and set a $40.00 price objective on shares of Moderna in a research report on Tuesday, February 18th. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Argus downgraded Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Finally, The Goldman Sachs Group cut Moderna from a "buy" rating to a "neutral" rating and cut their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.